Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer

NCT03507465 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

290

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Letrozole Plus Low-Dose Metronomic Capecitabine
DRUG: EC-T

Sponsor

Guangdong Provincial People's Hospital